Rubinstein-Taybi 2 associated to novel EP300 mutations: deepening the clinical and genetic spectrum, BMC Medical Genetics

Por um escritor misterioso
Last updated 22 dezembro 2024
Rubinstein-Taybi 2 associated to novel EP300 mutations: deepening the  clinical and genetic spectrum, BMC Medical Genetics
Background Rubinstein-Taybi syndrome (RSTS) is a rare autosomal dominant neurodevelopmental disorder characterized by broad thumbs and halluces. RSTS is caused by mutations in CREBBP and in EP300 genes in 50–60% and 8%, respectively. Up to now, 76 RSTS-EP300 patients have been described. We present the clinical and molecular characterization of a cohort of RSTS patients carrying EP300 mutations. Methods Patients were selected from a cohort of 72 individuals suspected of RSTS after being negative in CREBBP study. MLPA and panel-based NGS EP300 were performed. Results Eight patients were found to carry EP300 mutations. Phenotypic characteristics included: intellectual disability (generally mild), postnatal growth retardation, infant feeding problems, psychomotor and language delay and typical facial dysmorphisms (microcephaly, downslanting palpebral fissures, columella below the alae nasi, and prominent nose). Broad thumbs and/or halluces were common, but angulated thumbs were only found in two patients. We identified across the gene novel mutations, including large deletion, frameshift mutations, nonsense, missense and splicing alterations, confirming de novo origin in all but one (the mother, possibly underdiagnosed, has short and broad thumbs and had learning difficulties). Conclusions The clinical evaluation of our patients corroborates that clinical features in EP300 are less marked than in CREBBP patients although it is difficult to establish a genotype-phenotype correlation although. It is remarkable that these findings are observed in a RSTS-diagnosed cohort; some patients harbouring EP300 mutations could present a different phenotype. Broadening the knowledge about EP300-RSTS phenotype may contribute to improve the management of patients and the counselling to the families.
Rubinstein-Taybi 2 associated to novel EP300 mutations: deepening the  clinical and genetic spectrum, BMC Medical Genetics
Exon deletions of the EP300 and CREBBP genes in two children with Rubinstein -Taybi syndrome detected by aCGH. - Abstract - Europe PMC
Rubinstein-Taybi 2 associated to novel EP300 mutations: deepening the  clinical and genetic spectrum, BMC Medical Genetics
Bi-allelic TTC5 variants cause delayed developmental milestones and intellectual disability. - Abstract - Europe PMC
Rubinstein-Taybi 2 associated to novel EP300 mutations: deepening the  clinical and genetic spectrum, BMC Medical Genetics
A novel CREBBP mutation and its phenotype in a case of Rubinstein–Taybi syndrome, BMC Medical Genomics
Rubinstein-Taybi 2 associated to novel EP300 mutations: deepening the  clinical and genetic spectrum, BMC Medical Genetics
Identification of de novo EP300 and PLAU variants in a patient with Rubinstein–Taybi syndrome-related arterial vasculopathy and skeletal anomaly
Rubinstein-Taybi 2 associated to novel EP300 mutations: deepening the  clinical and genetic spectrum, BMC Medical Genetics
Genes, Free Full-Text
Rubinstein-Taybi 2 associated to novel EP300 mutations: deepening the  clinical and genetic spectrum, BMC Medical Genetics
Rubinstein–Taybi syndrome in diverse populations - Tekendo‐Ngongang - 2020 - American Journal of Medical Genetics Part A - Wiley Online Library
Rubinstein-Taybi 2 associated to novel EP300 mutations: deepening the  clinical and genetic spectrum, BMC Medical Genetics
High frequency of copy number imbalances in Rubinstein–Taybi patients negative to CREBBP mutational analysis
Rubinstein-Taybi 2 associated to novel EP300 mutations: deepening the  clinical and genetic spectrum, BMC Medical Genetics
Genes, Free Full-Text
Rubinstein-Taybi 2 associated to novel EP300 mutations: deepening the  clinical and genetic spectrum, BMC Medical Genetics
Epigenetic Mechanisms of Rubinstein–Taybi Syndrome

© 2014-2024 progresstn.com. All rights reserved.